Literature DB >> 2536840

Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivo.

T J Velu1, W C Vass, D R Lowy, P E Tambourin.   

Abstract

The rat-derived Harvey murine sarcoma virus (Ha-MuSV) contains a transduced ras oncogene activated by two missense mutations and flanked by rat retroviruslike VL30 sequences. Ha-MuSV induces focal transformation of mouse NIH 3T3 cells in vitro and tumors (fibrosarcomas and splenic erythroleukemias) in newborn mice. We have used these two assays to study the contribution of coding and noncoding viral sequences to the biological activity of Ha-MuSV. A good correlation was found between the in vitro and in vivo assays. In several different isogenic Ha-MuSV variants, those with a rasH gene that had one or both of the Ha-MuSV missense mutations were much more active biologically than the corresponding proto-oncogene. A Ha-MuSV variant that encoded the proto-oncogene protein induced lymphoid leukemias (with thymomas), with a relatively long latent period, rather than the fibrosarcomas and erythroleukemias characteristic of Ha-MuSV with one or both missense mutations. A VL30-derived segment with enhancer activity was identified downstream from v-rasH. A mutant Ha-MuSV from which this 3' noncoding segment was deleted expressed lower levels of the wild-type viral protein, displayed impaired transforming activity in vitro, and induced lymphoid leukemias (with thymomas). 5' noncoding rat c-rasH sequences were found to increase the biological activity of the virus when substituted for the corresponding segment of v-rasH. We conclude that (i) the biological activity of Ha-MuSV can be influence significantly by noncoding sequences located outside the long terminal repeat as well as by coding sequences, (ii) VL30 sequences positively regulate the expression of v-rasH, (iii) relatively low biological levels of ras, whether resulting from low-level expression of wild type v-rasH or high-levels of ras proto-oncogene protein, induce a type of tumor that differs from tumors induced by high biological levels of ras, and (iv) the in vivo pathogenicity of the Ha-MuSV variants correlated with their transforming activity on NIH 3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536840      PMCID: PMC247837     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  The ras gene family.

Authors:  D R Lowy; B M Willumsen
Journal:  Cancer Surv       Date:  1986

2.  Nucleotide sequence of the two rat cellular rasH genes.

Authors:  M Ruta; R Wolford; R Dhar; D Defeo-Jones; R W Ellis; E M Scolnick
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

3.  Biological properties of human c-Ha-ras1 genes mutated at codon 12.

Authors:  P H Seeburg; W W Colby; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Nov 1-7       Impact factor: 49.962

Review 4.  Oncogenes and cancer: the p21 ras genes.

Authors:  T Y Shih; M O Weeks
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

5.  Host-specific activation of transcription by tandem repeats from simian virus 40 and Moloney murine sarcoma virus.

Authors:  L A Laimins; G Khoury; C Gorman; B Howard; P Gruss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  NIH 3T3 cell line.

Authors:  J W Littlefield
Journal:  Science       Date:  1982-10-15       Impact factor: 47.728

7.  The p21 ras C-terminus is required for transformation and membrane association.

Authors:  B M Willumsen; A Christensen; N L Hubbert; A G Papageorge; D R Lowy
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

8.  Expression of normal and transforming H-ras genes in Escherichia coli and purification of their encoded p21 proteins.

Authors:  J C Lacal; E Santos; V Notario; M Barbacid; S Yamazaki; H Kung; C Seamans; S McAndrew; R Crowl
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

9.  Pathogenicity of retroviruses containing either the normal human c-Ha-ras1 gene or its mutated form derived from the bladder carcinoma EJ/T24 cell line.

Authors:  E H Chang; P L Morgan; E J Lee; K F Pirollo; E A White; D H Patrick; P N Tsichlis
Journal:  J Exp Pathol       Date:  1985

10.  The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer.

Authors:  P Hawley-Nelson; E J Androphy; D R Lowy; J T Schiller
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

View more
  23 in total

1.  Dominant transformation by mutated human ras genes in vitro requires more than 100 times higher expression than is observed in cancers.

Authors:  V Y Hua; W K Wang; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  A highly efficient retroviral vector allows detection of the transforming activity of the human c-fps/fes proto-oncogene.

Authors:  R A Feldman; D R Lowy; W C Vass; T J Velu
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  A ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1.

Authors:  J E DeClue; J C Stone; R A Blanchard; A G Papageorge; P Martin; K Zhang; D R Lowy
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

4.  Functional role of GTPase-activating protein in cell transformation by pp60v-src.

Authors:  J E DeClue; W C Vass; M R Johnson; D W Stacey; D R Lowy
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

5.  Transfected human beta-polymerase promoter contains a ras-responsive element.

Authors:  P S Kedar; D R Lowy; S G Widen; S H Wilson
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

6.  Oncogenicity of human N-ras oncogene and proto-oncogene introduced into retroviral vectors.

Authors:  M Souyri; I Vigon; M Charon; P Tambourin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Development of transforming function during transduction of proto-ras into Harvey sarcoma virus.

Authors:  M Lang; I Treinies; P H Duesberg; R Kurth; K Cichutek
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Roles of PSF protein and VL30 RNA in reversible gene regulation.

Authors:  Xu Song; Ying Sun; Alan Garen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-03       Impact factor: 11.205

9.  mRNA molecules containing murine leukemia virus packaging signals are encapsidated as dimers.

Authors:  Catherine S Hibbert; Jane Mirro; Alan Rein
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  The bovine papillomavirus E5 oncogene can cooperate with ras: identification of p21 amino acids critical for transformation by c-rasH but not v-rasH.

Authors:  B M Willumsen; W C Vass; T J Velu; A G Papageorge; J T Schiller; D R Lowy
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.